Australian Clinical Labs Ltd (ACL) AI Stock Analysis

• Market Cap: AU$524.72M
• Dividend Yield: 4.43%
• Average Volume (3M): 867.30K
• Price to Earnings (P/E): 15.6
• Beta (1Y): 1.04
• Revenue Growth: 6.73%
• EPS Growth: 37.16%
• Country: AU
• Employees: 4,900
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.12
• Shares Outstanding: 195,791,380
• 10 Day Avg. Volume: 799,589
• 30 Day Avg. Volume: 867,296
• PEG Ratio: 0.39
• Price to Book (P/B): 3.09
• Price to Sales (P/S): 0.71
• P/FCF Ratio: 3.03
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$3.43
• Price Target Upside: 21.63% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 71 Outperform
• Price Target: AU$3.00 ▲(6.38% Upside)

Australian Clinical Labs Ltd receives a score of 71, driven by strong technical indicators and a balanced valuation. While financial performance shows stability, high leverage and low net profit margins are concerns. The absence of earnings call and corporate events data limits further insights.

Positive Factors

Revenue Growth

Consistent revenue growth indicates a strong market position and the ability to expand service offerings, supporting long-term business sustainability.

Cash Flow Generation

Improved cash generation capabilities enhance financial flexibility, allowing for reinvestment in growth opportunities and debt reduction.

Operational Efficiency

Enhanced cost management and operational efficiency contribute to improved profitability, supporting sustainable business operations.

Negative Factors

High Leverage

Significant leverage could pose financial risks, limiting the company's ability to invest in growth and increasing vulnerability to economic downturns.

Low Net Profit Margin

Low net profit margins indicate challenges in converting revenue into profit, potentially impacting long-term profitability and shareholder returns.

Reliance on Debt Financing

Dependence on debt financing can increase financial risk, especially in volatile markets, and may constrain future growth and investment opportunities.

Australian Clinical Labs Ltd Business Overview & Revenue Model

Company Description

Australian Clinical Labs Ltd (ACL) is a leading provider of pathology services in Australia, specializing in diagnostic testing and laboratory services. The company operates a comprehensive network of laboratories and collection centers across the country, catering to both private and public healthcare sectors. ACL offers a wide range of services, including biochemistry, hematology, microbiology, and genetic testing, aimed at supporting healthcare providers with accurate and timely results to improve patient outcomes.

How the Company Makes Money

ACL generates revenue primarily through the provision of pathology testing services to healthcare providers, including hospitals, clinics, and general practitioners. The company charges fees for its diagnostic tests, which are often reimbursed by Medicare and private health insurers. Key revenue streams include routine pathology tests, specialized tests, and the provision of ancillary services such as sample collection and transportation. Additionally, ACL may engage in partnerships with healthcare organizations and participate in government initiatives that further enhance its service offerings and revenue potential. The volume of tests performed and the efficiency of its operations also play crucial roles in driving profitability.

Australian Clinical Labs Ltd Financial Statement Overview

Summary

Australian Clinical Labs Ltd demonstrates a stable financial position with resilience in revenue growth and cash flow generation. However, high leverage and low net profit margins pose risks. Continued focus on improving profitability and managing debt levels will be crucial for future stability and growth.

Income Statement

Australian Clinical Labs Ltd has shown a mixed performance in its income statement. The company experienced a slight revenue growth of 1.79% in the most recent year, following a decline in the previous periods. Gross profit margin improved significantly to 36.54%, indicating better cost management. However, the net profit margin remains low at 4.37%, suggesting challenges in translating revenue into profit. The EBIT and EBITDA margins are moderate, reflecting stable operational efficiency.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio of 1.69, indicating significant leverage, which could pose a risk if not managed properly. Return on equity is relatively strong at 18.93%, showing effective use of equity to generate profits. However, the equity ratio is low, suggesting a higher reliance on debt financing.

Cash Flow

Cash flow analysis shows a positive trend with an 8.67% growth in free cash flow, indicating improved cash generation capabilities. The operating cash flow to net income ratio is strong at 0.84, suggesting good cash conversion from earnings. The free cash flow to net income ratio is high at 0.95, reflecting efficient cash management.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	741.27M	741.27M	689.73M	692.10M	989.30M	641.31M
Gross Profit	270.86M	270.86M	138.45M	566.02M	781.71M	521.73M
EBITDA	81.36M	81.36M	169.65M	184.93M	372.75M	196.67M
Net Income	32.43M	32.43M	23.93M	35.90M	178.24M	60.37M
Balance Sheet
Total Assets	574.84M	574.84M	593.06M	578.91M	628.04M	474.70M
Cash, Cash Equivalents and Short-Term Investments	22.12M	22.12M	26.84M	20.59M	27.51M	36.28M
Total Debt	290.38M	290.38M	308.90M	316.32M	262.38M	294.26M
Total Liabilities	402.86M	402.86M	415.30M	406.24M	395.49M	392.79M
Stockholders Equity	171.35M	171.35M	177.53M	172.42M	232.44M	81.90M
Cash Flow
Free Cash Flow	174.39M	174.39M	153.09M	136.75M	262.83M	144.36M
Operating Cash Flow	182.80M	182.80M	159.59M	143.68M	284.09M	153.86M
Investing Cash Flow	-8.89M	-8.89M	-7.25M	-12.18M	-72.04M	-6.08M
Financing Cash Flow	-178.74M	-178.74M	-146.14M	-137.88M	-220.91M	-147.37M

Australian Clinical Labs Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.82
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ACL, the sentiment is Positive. The current price of 2.82 is above the 20-day moving average (MA) of 2.79, above the 50-day MA of 2.66, and above the 200-day MA of 2.73, indicating a bullish trend. The MACD of 0.05 indicates Positive momentum. The RSI at 55.29 is Neutral, neither overbought nor oversold. The STOCH value of 22.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ACL.

Australian Clinical Labs Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACL	71 Outperform	AU$524.72M	15.63	18.59%	4.43%	6.73%	37.16%
SHL	64 Neutral	AU$10.27B	19.43	6.32%	4.65%	9.44%	-0.37%
IDX	55 Neutral	AU$977.07M	172.37	0.94%	2.65%	33.54%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HLS	50 Neutral	€635.37M	-1.21	-67.21%	―	-23.02%	33.11%

Australian Clinical Labs Ltd Corporate Events

Australian Clinical Labs Updates on Share Buy-Back Progress

Australian Clinical Labs Ltd has announced an update regarding its ongoing on-market buy-back program. As of December 4, 2025, the company has repurchased a total of 1,932,484 ordinary fully paid securities, including 150,000 bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and enhance shareholder value.

Australian Clinical Labs Updates on Share Buy-Back Progress

Australian Clinical Labs Ltd has announced an update on its ongoing share buy-back program, revealing that a total of 289,740 ordinary fully paid securities were bought back on the previous day, bringing the total number of securities bought back to 1,492,744. This buy-back initiative is part of the company’s strategy to enhance shareholder value and optimize its capital structure, potentially impacting its market positioning and investor relations positively.

Australian Clinical Labs Ltd Updates on Buy-Back Program

Australian Clinical Labs Ltd has announced an update regarding its ongoing on-market buy-back program. As of December 2, 2025, the company has repurchased a total of 1,492,744 ordinary fully paid securities, including 175,000 securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.

Australian Clinical Labs Updates on Share Buy-Back Progress

Australian Clinical Labs Limited has announced an update regarding its ongoing share buy-back program. As of November 27, 2025, the company has repurchased a total of 1,231,319 shares, with 27,843 shares bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.

Australian Clinical Labs Updates on Share Buy-Back Program

Australian Clinical Labs Ltd announced an update on its ongoing share buy-back program, revealing that a total of 1,006,789 securities had been bought back before the previous day, with an additional 196,687 securities purchased on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.

Australian Clinical Labs Announces Cessation of Securities

Australian Clinical Labs Ltd announced the cessation of 550,000 fully paid ordinary securities as part of an on-market buy-back, effective November 19, 2025. This move is likely aimed at optimizing the company’s capital structure and could have implications for shareholder value and market perception.

Australian Clinical Labs Issues New Securities

Australian Clinical Labs Limited announced the issuance and conversion of unquoted equity securities, with a total of 83,853 ordinary fully paid securities being issued on specified dates in 2023. This move could impact the company’s financial structure and shareholder value, potentially influencing its market positioning and stakeholder interests.

Australian Clinical Labs Updates on Share Buy-Back Progress

Australian Clinical Labs Ltd has announced an update regarding its ongoing on-market buy-back program. As of November 18, 2025, the company has repurchased a total of 549,627 ordinary fully paid securities, with an additional 200,000 securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.

Australian Clinical Labs Ltd Updates on Buy-Back Program

Australian Clinical Labs Ltd has announced an update regarding its ongoing on-market buy-back program. As of November 14, 2025, the company has repurchased a total of 399,627 ordinary fully paid securities, with 200,000 bought back on the previous day. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.

Australian Clinical Labs Announces Daily Buy-Back Update

Australian Clinical Labs Limited has announced an update regarding their on-market buy-back of ordinary fully paid securities, with a total of 199,627 securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure, potentially enhancing shareholder value and signaling confidence in its financial health.

Australian Clinical Labs Issues Unquoted Equity Securities

Australian Clinical Labs Ltd has announced the issuance and conversion of unquoted equity securities, with a total of 187,668 ordinary fully paid securities being issued. This move may impact the company’s financial structure and could have implications for its market positioning and shareholder value.

Director Increases Stake in Australian Clinical Labs

Australian Clinical Labs Ltd has announced a change in the director’s interest in securities. Stephen Roche, a director, has acquired 70,000 ordinary shares at $2.77 per share, marking his direct interest in the company through the Steann Superannuation Fund. This transaction, conducted on-market, indicates a significant personal investment by the director, potentially reflecting confidence in the company’s future performance.

Australian Clinical Labs Completes Share Buy-Back

Australian Clinical Labs Ltd has announced the final notification of its buy-back program, where a total of 6,042,629 ordinary fully paid securities were bought back for a total consideration of AUD 19,101,121.57. This buy-back is part of the company’s strategic financial management, potentially impacting its market positioning by reducing the number of outstanding shares, which may enhance shareholder value.

Australian Clinical Labs Announces 2025 AGM Results

Australian Clinical Labs Ltd announced the results of its 2025 Annual General Meeting, where several key resolutions were passed, including the re-election of directors Sarah Butler, Grant Jeffery, Stephen Roche, and Mark Haberlin, as well as the adoption of the 2025 Remuneration Report. The spill resolution was not carried. These outcomes reflect the company’s stable governance structure and commitment to maintaining its leadership team, which may reassure stakeholders about the company’s strategic direction and operational continuity.

ACL Adjusts AGM Agenda Following Director’s Resignation

Australian Clinical Labs Limited announced the withdrawal of Resolution 5 from its Annual General Meeting agenda following the resignation of Dr. Leanne Rowe AM. The meeting will proceed as planned on 23 October 2025. This change reflects an adjustment in the company’s governance structure, potentially impacting its strategic direction and stakeholder engagement.

Australian Clinical Labs Announces Board Resignation of Dr. Leanne Rowe AM

Australian Clinical Labs Limited announced the resignation of Dr. Leanne Rowe AM from its Board, effective immediately, due to personal reasons. Dr. Rowe, who joined the Board during the company’s IPO in April 2021, brought significant medical and leadership expertise, contributing greatly to the Board’s skill set and supporting the senior executive team. Her departure is noted as a loss for the company, which expressed gratitude for her contributions and wished her well in future endeavors.

ACL Resolves Cyberattack Penalty Case with $5.8 Million Settlement

Australian Clinical Labs Limited (ACL) has reached a resolution with the Australian Information Commissioner regarding a civil penalty proceeding related to a cyberattack on its Medlab Pathology business. The Federal Court of Australia has approved an agreement requiring ACL to pay $5.8 million in civil penalties and contribute $400,000 towards legal costs, concluding the proceedings and potentially impacting ACL’s financial standing and stakeholder relations.

Australian Clinical Labs Resolves Privacy Act Proceedings with AIC

Australian Clinical Labs Limited has reached an agreement with the Australian Information Commissioner to resolve a civil penalty proceeding related to a cyberattack on Medlab Pathology, which occurred shortly after ACL acquired the business. The agreement includes a proposed penalty of $5.8 million and a contribution of $400,000 towards legal costs, pending Federal Court approval. The cyberattack did not affect ACL’s systems, and the company has since integrated Medlab’s IT systems into its own robust cybersecurity framework. This resolution allows ACL to focus on its strategic goals and continue delivering high-quality pathology services.

Australian Clinical Labs Announces 2025 AGM Details and Annual Report Release

Australian Clinical Labs Limited has announced the details for its 2025 Annual General Meeting, including the AGM Notice of Meeting, Proxy Form, Shareholder Question Form, and an Online Guide from Link Market Services. The announcement also includes the release of the company’s 2025 Annual Report, which encompasses the Corporate Governance Statement. This release is significant for stakeholders as it provides insights into the company’s governance and operational strategies, potentially impacting its market positioning and stakeholder engagement.

Australian Clinical Labs Announces 2025 Annual General Meeting

Australian Clinical Labs Limited has announced its 2025 Annual General Meeting, scheduled for October 23, 2025. The announcement includes details such as the AGM notice, proxy form, shareholder question form, and an online guide from Link Market Services. This meeting and the accompanying 2025 Annual Report, which includes the Corporate Governance Statement, are significant for stakeholders as they provide insights into the company’s governance and strategic direction.

Australian Clinical Labs Releases 2025 AGM Documents and Annual Report

Australian Clinical Labs Limited has released several documents related to its 2025 Annual General Meeting, including the AGM Notice of Meeting, Proxy Form, Shareholder Question Form, and an Online Guide from Link Market Services. The company also published its 2025 Annual Report, which includes the Corporate Governance Statement. This release indicates ACL’s commitment to transparency and adherence to corporate governance standards, potentially strengthening its position within the pathology services industry and providing stakeholders with confidence in its operational integrity.